Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of filgotinib in rheumatoid arthritis
MOH_2017-09-10_000428Phase 3Active, not recruiting
- Sponsor
- Alfasigma
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of filgotinib in rheumatoid arthritis (RA) (2 arms), sponsored by Alfasigma. Started Aug 2017; status: active, not recruiting.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on MOH_2017-09-10_000428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-10_000428.